本帖最后由 老马 于 2013-3-13 13:43 编辑
. k+ i# V. I ?( y
- ^5 {7 q" f1 B* _: u, r健择(吉西他滨)+顺铂+阿瓦斯汀3 e8 L* |. ^/ s) x& y
Gemzar +Cisplatin + Avastin
0 }) N" G$ s6 G Q/ c1 d7 phttp://annonc.oxfordjournals.org/content/21/9/1804.full8 ?4 s) _6 l- z* p$ O5 B k: Z- a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 u( y& r& v F- ^/ y7 C
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
y- ?( ?6 o7 q7 N+ jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) o1 [7 d0 ?- e9 ]
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 614)
! u$ x f4 E4 t# F& q$ l华为网盘附件:& o3 Z6 @) u7 ^7 z5 \
【华为网盘】ava.JPG5 E7 O$ k8 U0 {* ~
|